Over the years, American Society of Clinical Oncology (ASCO) conferences have provided numerous insights that have refined and expanded the standard of care for cancer treatment. The 2022 ASCO Genitourinary Cancers Symposium, held February 17-19 in San Francisco, CA, and online, was no exception, with tracks dedicated to the latest research on therapies for cancers of the kidney, adrenal glands, penis, testicles, and urethra. Here we summarize one presentation, by Michael B. Atkins, MD, of the Georgetown Lombardi Comprehensive Cancer Center in Washington DC. [1]

Michael B. Atkins, MD, of the Georgetown Lombardi Comprehensive Cancer Center in Washington DC

The talk, Long-term PFS from TIVO-3: Tivozanib (TIVO) versus Sorafenib (SOR) in Relapsed/Refractory (R/R) Advanced RCC, presented data from the TIVO-3 study comparing long-term progression-free survival (PFS) of two kinase inhibitors in renal cell carcinoma (RCC): tivozanib (Fotivda®, AVEO Pharmaceuticals) vs. sorafenib (Nexavar®, Bayer HealthCare Pharmaceuticals).

Clinically Relevant PFS
Long-term PFS is clinically meaningful in RCC, and the basis on which tivozanib was approved by the U.S. Food and Drug Administration in March, 2021. This study focused on this endpoint at six month intervals, up to four years after initiating treatment, among patients with relapsed/refractory metastatic RCC who had undergone at least two courses of prior therapy.

Investigators randomized 350 patients equally to tivozanib or sorafenib, and found superior PFS at every time point, for example at six months (49.6% vs. 35.1% in favor of tivozanib), 12 months (31.2% vs. 18.4%), 18 months (24.2% vs. 8.8%), 24 months (18.3% vs. 4.8%), 30 months (13.9% vs. 3.2%), 36 months (12.3% vs. 2.4%), 42 months (9.2% vs. 1.6%), and 48 months (7.6% vs. 0%).

The results were significant to the 95% confidence level except for 42 and 48 months, when the number of patients was too small to provide statistical power. Despite the low numbers generally by the three-year point, the data revealed particularly favorable outcomes, but only within the tivozanib group, among females, patients older than 65, and those with favorable IMDC (International Metastatic RCC Database Consortium) risk scores.[1]

Advertisement #3

These results are consistent with independent review board assessments of PFS in this patient group. They show that tivozanib-treated patients are up to five times more likely to experience long-term PFS compared with those treated with sorafenib.[1]

Metastatic disease develops in one-third of patients presenting with RCC. The prognosis for these patients is almost uniformly poor, with median survival of just six to twelve months, and two-year survival between 10% and 20%. This study demonstrated that these odds could be improved, with a small but clinically relevant number of them still alive and progression-free three and four years after initiation of treatment with tivozanib.

Clinical trials
A Study to Compare Tivozanib Hydrochloride to Sorafenib in Subjects With Refractory Advanced RCC – NCT02627963

Highlights of prescribing information
Tivozanib (Fotivda®, AVEO Pharmaceuticals) (Prescribing information)
Sorafenib (Nexavar®, Bayer HealthCare Pharmaceuticals) (Precscribing Information)

[1] Atkins MB, Verzoni E, Escudier B, McDermott DF, Hutson TE, Pal SK, Porta C, Asnis-Alibozek AG, Kasturi V, Rini BI. Long-term PFS from TIVO-3: Tivozanib (TIVO) versus sorafenib (SOR) in relapsed/refractory (R/R) advanced RCC. Journal of Clinical Oncology 2022 40:6_suppl, 362-362

Featured image: Attendees looking at posters during Poster Session at the 2020 Genitourinary Cancers Symposium, February 13, 2020. Photo courtesy: by © 2020 ASCO/Todd Buchanan. Used with permission.

Advertisement #5